Loading clinical trials...
Loading clinical trials...
LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Interventions
BNT116
Cemiplimab
+9 more
Locations
44
United States
University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
MD Anderson Cancer Center
Houston, Texas, United States
NEXT Virginia
Fairfax, Virginia, United States
Scientia Clinical Research
Randwick, New South Wales, Australia
Start Date
June 17, 2022
Primary Completion Date
February 1, 2030
Completion Date
November 1, 2031
Last Updated
April 14, 2026
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT06253871
Lead Sponsor
BioNTech SE
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions